united states: fda panel recommends gilead's quad for hiv

CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update UNITED STATES: FDA Panel Recommends Gilead's Quad for HIV David Morgan
May 14, 2012

Reuters, (05.11.2012) - Monday, May 14, 2012 A Food and Drug Administration advisory panel on Friday voted 13-1 to recommend Gilead Sciences Inc.’s Quad pill for people with HIV who have never been treated. However, the independent experts said patients taking the drug should be monitored for possible kidney problems, and they urged more research to assess the safety of Quad for women, who were under-represented in clinical trials. The panel’s sole “no” voter said data on potential kidney problems and on women’s health were too limited to justify approval. “There are plenty of alternatives to Quad,” said Dr. Michelle Estrella of Johns Hopkins University School of Medicine. “There’s no huge hurry in approving this drug before the outstanding studies are completed.” The pill is a combination of four agents: an experimental integrase inhibitor (elvitegravir), a booster (cobicistat), and two nucleotide reverse transcriptase inhibitors (emtricitabine and tenofovir). In clinical trials, Quad was 88 percent effective in suppressing HIV, besting Gilead HIV treatment Atripla’s efficacy of 84 percent. Nonetheless, trial data suggest there were a disproportionate number of kidney problems. The once-daily pill schedule would help patients adhere to Quad, boosting treatment efficacy, said Gilead. The firm said it has not set a possible price for Quad. In an era of restricted public assistance for treatment, AIDS advocates worry about the cost of new AIDS drugs that offer only modest improvements in treatment. The panel’s recommendation will be taken up by FDA regulators, and a decision on final approval is expected August 27.

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Photographs from A Day with HIV Now Online Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 ARIZONA: Routine Skin Testing Available Again at Tuberculosis Clinic Starting May 20 NORTH DAKOTA: Officials: 26 Tuberculosis Cases from Grand Forks Outbreak AUSTRALIA: HIV Rates Triple in the Northern Territory in Just 12 Months ARIZONA: Parsons Foundation Gives $3 Million to Southwest Center for HIV/AIDS UNITED STATES: Triple Therapy for Hepatitis C is Effective After Liver Transplantation, but Side-Effects Are Common CANADA: Nunavut Uses Comic Book to Do Sex Education NEW HAMPSHIRE: State Health Officials Urge Hepatitis Testing UNITED STATES: Hepatitis C Testing for People Born Between 1945 and 1965 People with HIV pay more for life insurance – if they can get it (South Africa)Uganda: Gov't Urged to Levy a Tax On Alcohol to Fund HIV AUSTRALIA: HIV Rates Triple in the Northern Territory in Just 12 Months ARIZONA: Parsons Foundation Gives $3 Million to Southwest Center for HIV/AIDS UNITED STATES: Triple Therapy for Hepatitis C is Effective After Liver Transplantation, but Side-Effects Are Common NEW HAMPSHIRE: State Health Officials Urge Hepatitis Testing UNITED STATES: Hepatitis C Testing for People Born Between 1945 and 1965 People with HIV pay more for life insurance – if they can get it (South Africa)Uganda: Gov't Urged to Levy a Tax On Alcohol to Fund HIV No time to lose in the search for an HIV vaccine Health group didn't disclose HIV tests, apologizes NEW JERSEY: Drug Company Donates Thousands to HIV/AIDS Orgs
Copyright © 2012 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles. Information in this article was accurate in May 14, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.